Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

1.1 Research Scope

1.2 Research Methodology

1.2 Research Methodology (Continued)

1.3 Key Findings

2.1 Alzheimer’s and Parkinson’s Diseases Are Leading Causes of Neurodegenerative Disorders

2.2 Disease-modifying Therapies Likely to Lead Emerging Landscape for AD and PD Management

2.3 Healthcare Burden for AD and PD Likely to Increase in the Future

3.1 Summary of Key Technology Drivers and Restraints

3.2 Technological Advancements Likely to Fuel New Therapeutics for Neurodegenerative Disorders

3.3 Clinical Trial Advancements of Novel Neurological Therapies Limited by High Failure Rates

4.1 Cholinesterase Inhibitors Lead Existing Treatment Platforms for Alzheimer’s Disease

4.2 Disease-modifying Agents Likely to Have High Impact across AD Patients

4.3 US Leads the Patent Landscape for Novel AD Therapies

4.4 Denali Therapeutics Leads the Global Venture Landscape for AD Treatment

4.5 Amyloid Therapies Lead the Emerging AD Treatment Landscape

4.6 Clinical Pipeline Overview for AD

4.7 Small Molecule RIP1 Inhibitor for Treating AD

4.8 Novel Second Generation Tau-aggregation Inhibitor for AD Management

4.9 Immunomodulatory Strategies for Clinical Management of AD

4.10 Targeting Amyloid Aggregates for Clinical Management of Neurodegeneration

5.1 Levadopa Leads the Existing PD Treatment Landscape

5.2 Biologics Pipeline Likely to Garner Increased Focus across the Emerging PD Treatment Landscape

5.3 Emerging Disease-modifying Small Molecules Likely to Lead PD Management

5.4 US Leads the Patent Landscape for Novel PD Therapies

5.5 Significant NIH and Venture Funding Indicative of Growing Focus on PD Therapeutics

5.6 Clinical Pipeline Overview for PD

5.7 Viral Gene Therapy for PD

5.8 Integrated Therapeutic Platform for Neurodegenerative Diseases

5.9 Novel Wearable for Tremor Management

5.10 Targeted Vaccine Platform for PD

6.1 Overview of the Collaborative Landscape

6.2 Developed Economies Likely to Lead Global Adoption Scenario for Neurodegenerative Therapies

6.3 New Symptomatic and Disease-Modifying Treatments for AD and PD on the Horizon

7.1 Growth Opportunity 1: Disease-modifying Therapy

7.2 Growth Opportunity 2: Immunotherapies

7.3 Growth Opportunity 3: Gene Therapies

7.4 Strategic Imperatives for Success and Growth

8.1 Key Contacts

8.1 Key Contacts (Continued)

Legal Disclaimer

9.1 The Frost & Sullivan Story

9.2 Value Proposition: Future of Your Company & Career

9.3 Global Perspective

9.4 Industry Convergence

9.5 360º Research Perspective

9.6 Implementation Excellence

9.7 Our Blue Ocean Strategy